+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Should Treatment with Radiation and Androgen Deprivation Therapy be Considered the 'Gold Standard' for Men with Unfavourable Intermediate- to High-risk and Locally Advanced Prostate Cancer?



Should Treatment with Radiation and Androgen Deprivation Therapy be Considered the 'Gold Standard' for Men with Unfavourable Intermediate- to High-risk and Locally Advanced Prostate Cancer?



Clinical Oncology ) 28(8): 475-478




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058847801

Download citation: RISBibTeXText

PMID: 27133945

DOI: 10.1016/j.clon.2016.04.037


Related references

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer 120(11): 1620-1629, 2014

Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer. International Journal of Urology 22(5): 477-482, 2016

Multimodal treatment for high risk locally advanced prostate cancer following radical prostatectomy and extended lymphadenectomy: results of a prospective cohort study with high-dose intensity-modulated radiation therapy, concurrent docetaxel and long-term androgen deprivation therapy. Minerva Urologica E Nefrologica 2019, 2019

Primary androgen deprivation therapy as monotherapy in unfavourable intermediate- and high-risk localised prostate cancer: a Singaporean single-centre perspective. International Urology and Nephrology 50(4): 665-673, 2018

Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer. Cancer 122(15): 2296-2298, 2017

Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer. Clinical Oncology ) 28(6): 376-385, 2017

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy. Radiation Oncology 11: 78, 2017

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis. International Braz J Urol 41(3): 425-434, 2015

A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics 97(5): 962-975, 2017

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer. Advances in Radiation Oncology 1(4): 300-309, 2017

The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiation Oncology 7: 66, 2012

A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″. International Braz J Urol 40(1): 3-15; Discussion 15, 2014

Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer. Urologic Oncology 2017, 2017

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378(9809): 2104-2111, 2012

ACP Journal Club. Radiation plus androgen deprivation therapy reduced mortality in locally advanced prostate cancer. Annals of Internal Medicine 156(8): Jc4-05, Jc4-04, 2012